These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 19671735)

  • 1. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
    Bates D; Eastman A
    Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    Dumontet C; Sikic BI
    J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitubulin agents].
    Dumontet C
    Bull Cancer; 2011 Nov; 98(11):1275-85. PubMed ID: 22023745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubulin Proteins in Cancer Resistance: A Review.
    Kamal MA; Al-Zahrani MH; Khan SH; Khan MH; Al-Subhi HA; Kuerban A; Aslam M; Al-Abbasi FA; Anwar F
    Curr Drug Metab; 2020; 21(3):178-185. PubMed ID: 32101117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
    Liaw TY; Chang MH; Kavallaris M
    Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting microtubules for cancer chemotherapy.
    Zhou J; Giannakakou P
    Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.